The Teva Biosimilars Trend Report, Second Edition: Perspectives from Managed Care, Providers & Employers
On behalf of Teva Pharmaceuticals, we are pleased to present the second edition of The Teva Biosimilars Trend Report. This report examines the latest issues, challenges, and developments in the rapidly evolving biosimilars market from the perspective of managed care professionals, healthcare providers, and employers. The goal of the report is to provide key insights into the issues affecting biosimilar coverage, prescription, and utilization from each of the 3 groups of stakeholders.1
The report features national surveys conducted in the summer of 2024 with 54 decision-makers at managed care plans, 73 prescribers of biologic therapies (from rheumatology, gastroenterology, and dermatology specialties), and 39 executives representing employers and business coalitions. It also includes:
- Sections covering the perspectives of managed care payers, healthcare providers, and employers.
- Responses analyzed by independent experts representing each topic area. Nine experts also provide commentary on the findings and share their own experiences in the biosimilars space.
- An insightful article on the real and potential effects of the Inflation Reduction Act on biosimilar development and market access.
- A critical discussion of biosimilar sustainability, with a focus on prospects for the pharmacy benefit– covered products.
Reference
- Sonnenreich P, Leo S, Sebor C, Mehr S, eds. The Teva Biosimilars Trend Report, Vol. 2. 2025.